GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest version of its transcatheter aortic valve replacement implant. Compared to ...
Study validates a new risk model that allows for more accurate risk estimates, encourages shared decision-making, and helps ...
Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
Medtronic reported late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Dublin-based company said data shows, vs. surgery, the Evolut transcatheter aortic valve replacement ...
MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (AVR) (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company ...
Edwards, AtriCure, Boston Scientific, and Medtronic report strong earnings driven by TAVR, PFA, and cardiac ablation growth in 2025.
Medtronic plc received U.S. FDA approval for the expanded redo TAVR indication of the Evolut transcatheter aortic valve replacement system. The approval allows for valve-in-valve implantation of a new ...
On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients suffering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results